BLUE BELL, Pa.--(BUSINESS WIRE)--June 5, 2006--Locus Pharmaceuticals, Inc., a computationally-based drug design and development company, announced today that it has entered into a research agreement with Amgen, whereby Locus will apply its proprietary computational technologies to design novel small molecule compounds having activity against a target identified by Amgen. Financial and other terms of the agreement were not disclosed.
